{"id":3070,"date":"2026-09-08T00:00:00","date_gmt":"2026-09-08T04:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=3070"},"modified":"2026-09-12T10:41:05","modified_gmt":"2026-09-12T14:41:05","slug":"baff-r-car-t-shows-durable-responses-after-cd19-therapy","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=3070","title":{"rendered":"BAFF-R CAR T Shows Durable Responses After CD19 Therapy"},"content":{"rendered":"

Evidence<\/strong> Peer-reviewed publication · Discovery<\/strong> September 11, 2026 · Importance<\/strong> 5\/5 · Direction<\/strong> Positive<\/p>\n

\"BAFF-R<\/p>\n

Summary<\/h4>\n

A peer-reviewed Lancet research letter reported the completed dose-escalation cohort of PMB-CT01, an autologous BAFF-R-directed CAR-T therapy, in nine adults with relapsed or refractory B-cell non-Hodgkin lymphoma. Seven of nine patients achieved complete response, including four of six previously treated with CD19-directed CAR-T therapy, and all seven responses were ongoing at data cutoff; the longest had reached 35 months. Cytokine-release syndrome was limited to grade 1, and both reported neurotoxicity events were grade 1. The signal is clinically important because BAFF-R offers an alternative B-cell target after CD19 failure, but nine uncontrolled patients cannot establish comparative efficacy, cure, or outpatient suitability.<\/p>\n

What Happened<\/h4>\n

The Phase 1 study NCT05370430 was conducted initially at City of Hope and evaluated escalating doses of PMB-CT01 in heavily pretreated B-cell lymphoma. The publication follows earlier conference disclosure and adds peer review rather than a wholly new cohort. The program is expanding into mantle-cell, large B-cell and follicular lymphoma cohorts. The first reported expansion patient, with triple-hit high-grade B-cell lymphoma after CD19 CAR-T progression, also achieved a complete response at first assessment. PMB-CT01 targets the B-cell activating factor receptor, a survival receptor expressed predominantly on mature B cells; the sponsor argues that dependence on BAFF-R may reduce antigen-loss escape, but the study did not prove that mechanism in patients.<\/p>\n

Deep Analysis<\/h4>\n

A clinically useful rescue target after CD19 escape:<\/strong> The four complete responses among six patients previously exposed to CD19 CAR-T, combined with response durability beyond one year in several patients, support BAFF-R as a plausible salvage target. Low-grade acute toxicities also suggest the construct may have a workable therapeutic window. Counterevidence is the tiny, selected cohort, absence of a control group, heterogeneous lymphoma biology, and survivorship bias in emphasizing ongoing responders.<\/p>\n

An encouraging but fragile Phase 1 signal:<\/strong> The result could reflect favorable patient selection, disease sensitivity, conditioning, or manufacturing rather than target-specific resistance reversal. The research-letter format limits detail on baseline disease burden, prior therapies, cellular kinetics, B-cell aplasia and nonresponders. The responses occurred in a particularly difficult post-CAR population and persisted at cutoff, which warrants expansion but not a cure claim.<\/p>\n

Signal Extraction<\/h4>\n

Verified facts: peer-reviewed publication; nine treated patients; seven complete responses; four of six complete responses after prior CD19 CAR-T; longest ongoing response 35 months; only grade 1 reported CRS and ICANS in the disclosed cohort. Missing facts: confidence intervals, full follow-up distribution, relapse-free survival, cellular persistence, BAFF-R expression at relapse and manufacturing success. Upgrade evidence would be reproducible activity in a larger prespecified post-CD19 cohort with durable event-free survival and complete safety reporting.<\/p>\n

Company and Product Background<\/h4>\n

PeproMene Bio is a privately held clinical-stage biotechnology company developing BAFF-R-directed cell therapies and bispecific constructs. PMB-CT01 is an autologous CAR-T product licensed from City of Hope, being studied in relapsed or refractory B-cell lymphoma and separately in B-cell acute lymphoblastic leukemia.<\/p>\n

B-cell lymphomas can relapse after CD19-directed therapy through antigen loss, low antigen density, impaired T-cell fitness or broader tumor and microenvironmental resistance. BAFF-R is a distinct B-cell-lineage receptor required for survival signaling. Redirecting CAR-T cells to BAFF-R could bypass CD19-negative relapse, but on-target B-cell depletion, infectious risk, antigen heterogeneity and manufacturing burden remain relevant.<\/p>\n

InSilens Take<\/h4>\n

PMB-CT01 is one of the more credible early signals for target diversification after CD19 CAR-T failure, because the reported responses are deep, include a defined post-CD19 subgroup and have meaningful follow-up. The interpretation must remain bounded: the study is too small and uncontrolled to support the sponsor’s suggestion of cure or an outpatient advantage. The decisive evidence will come from the expansion cohorts, with transparent denominator accounting, molecular confirmation of BAFF-R biology, standardized response assessment and long-term safety.<\/p>\n

Signal Assessment<\/h4>\n\n\n\n\n\n
Signal Importance<\/strong><\/td>\n5 \/ 5 — the dataset addresses post-CD19 CAR-T relapse, a high-need hematologic setting, and provides rare multi-year follow-up for an alternative B-cell target<\/td>\n<\/tr>\n
Signal Direction<\/strong><\/td>\nPositive — the observed depth, durability and acute safety are favorable, without implying comparative benefit or cure<\/td>\n<\/tr>\n
Confidence in Facts<\/strong><\/td>\nHigh — the core cohort and outcomes are reported in a peer-reviewed Lancet research letter and linked trial record<\/td>\n<\/tr>\n
Confidence in Interpretation<\/strong><\/td>\nModerate-low — sample size, selection, uncontrolled design and incomplete long-term toxicity and manufacturing detail materially limit generalization<\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

A peer-reviewed Lancet research letter reported the completed dose-escalation cohort of PMB-CT01, an autologous BAFF-R-directed CAR-T therapy, in nine adults with relapsed or refractory B-cell non-Hodgkin lymphoma. Seven of nine patients achieved complete response,…<\/p>\n","protected":false},"author":1,"featured_media":3075,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,3],"tags":[726,725,723,724],"class_list":["post-3070","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-clinical","category-therapeutic-indication","tag-b-cell-lymphoma","tag-baff-r","tag-pepromene-bio","tag-pmb-ct01"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3070","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3070"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3070\/revisions"}],"predecessor-version":[{"id":3088,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3070\/revisions\/3088"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3075"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3070"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3070"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3070"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}